Kazano is owned by Takeda Pharms Usa.

Kazano contains Alogliptin Benzoate; Metformin Hydrochloride.

Kazano has a total of 17 drug patents out of which 13 drug patents have expired.

Expired drug patents of Kazano are:

• US6150384
• US6166043
• US6329404
• US6166042
• US6172090
• US6211205
• US5965584
• US6150383
• US6303640
• US6303661
• US7459428
• US6890898
• US7078381

Kazano was authorised for market use on 25 January, 2013.

Kazano is available in tablet;oral dosage forms.

Kazano can be used as methods of treating diabetes comprising administering an insulin sensitivity enhancer such as pioglitazone in combination with an insulin secretion enhancer, methods of treating lipid metabolism disorders comprising administering an insulin sensitivity enhancer such as pioglitazone in combination with a biguanide such as metformin, methods of treating lipid metabolism and glycometabolism disorders comprising administering an insulin sensitivity enhancer such as pioglitazone in combination with an insulin secretion enhancer, methods of reducing the side effects of active components administered to a diabetic patient comprising administering an insulin sensitivity enhancer such as pioglitazone in combination with an insulin secretion enhancer, methods of treating diabetes comprising administering an insulin sensitivity enhancer such as pioglitazone in combination with a biguanide such as metformin, methods of treating diabetes comprising administering a dipeptidyl peptidase inhibitor and metformin, methods of lowering elevated post prandial blood glucose levels comprising administering a dipeptidyl peptidase inhibitor, methods of reducing the amount of active components administered to a diabetic patient comprising administering an insulin sensitivity enhancer such as pioglitazone in combination with an insulin secretion enhancer, method of treating diabetes comprising administering a compound such as alogliptin, method of treating diabetes comprising administering alogliptin, methods of treating glycometabolism disorders comprising administering an insulin sensitivity enhancer such as pioglitazone in combination with a biguanide such as metformin, methods of reducing the amount of active components administered to a diabetic patient comprising administering an insulin sensitivity enhancer such as pioglitazone in combination with a biguanide such as metformin, methods of modifying glucose metabolism and treating diabetes comprising administering a dipeptidyl peptidase inhibitor and one or more other therapeutic agents such as metformin, methods of reducing the side effects of active components administered to a diabetic patient comprising administering an insulin sensitivity enhancer such as pioglitazone in combination with a biguanide such as metformin.

Drug patent challenges can be filed against Kazano from 25 January, 2017.

The generics of Kazano are possible to be released after 24 May, 2029.